Skip to main content
SpringerLink
Log in

NICE decisions on rucaparib and atezolizumab

  • News item
  • Published:
PharmacoEconomics & Outcomes News

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. NICE. Another treatment option for ovarian cancer approved for the Cancer Drugs Fund. Internet Document : 11 Oct 2019. Available from: URL: https://www.nice.org.uk/news/article/another-treatment-option-for-ovarian-cancerapproved-for-the-cancer-drugs-fund.

  2. NICE. NICE looks to company to ensure a new treatment for advanced breast cancer with significant unmet need is cost-effective. Internet Document : 3 Oct 2019. Available from: URL: https://www.nice.org.uk/news/article/nice-looks-tocompany- to-ensure-a-new-treatment-for-advanced-breast-cancer-with-significantunmet-need-is-cost-effective.

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

NICE decisions on rucaparib and atezolizumab. PharmacoEcon Outcomes News 839, 35 (2019). https://doi.org/10.1007/s40274-019-6316-5

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40274-019-6316-5

Search

Navigation